CHF 60.00
In stock
AG-CN2-0457-M05050 mgCHF 60.00
AG-CN2-0457-M250250 mgCHF 180.00
More Information
Product Details
Synonyms Emodol; Frangulic acid; Archin; NSC 622947; NSC 408120; 1,3,8-Trihydroxy-6-methylanthraquinone; Schuttgelb
Product Type Chemical


MW 270.2
Merck Index 14: 3561
CAS 518-82-1
RTECS CB7920600
Source/Host Chemicals Isolated from Polygonum cuspidatum.
Purity Chemicals ≥98%
Appearance Orange solid.
Solubility Soluble in DMSO or 100% ethanol. Insoluble in water.
Smiles CC1=CC2=C(C(O)=C1)C(=O)C1=C(C=C(O)C=C1O)C2=O
Shipping and Handling
Shipping AMBIENT
Short Term Storage +20°C
Long Term Storage +4°C
Handling Advice Keep cool and dry.
Protect from light.
Use/Stability Stable for at least 2 years after receipt when stored at +4°C.
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
  • p56lck protein kinase inhibitor.
  • Competitive casein kinase II (CK2) inhibitor.
  • Anticancer agent with apoptosis inducing with antiangiogenic activity.
  • Antioxidant, vasorelaxant and neuroprotective agent.
  • NF-κB activation inhibitor.
  • Inflammasome inhibitor.
  • Potent selective 11β-HSD1 inhibitor. Improves insulin sensitivity and lipid metabolism.
  • Estrogen receptor ERα and ERβ inhibitor.
  • Inhibits androgen receptor (AR) nuclear translocation and induces AR degradation.
  • VEGFR2, FGFR-1, EGFR, PDGFR-β and Kit inhibitor.
  • JAK2 inhibitor.
  • Anti-diabetic agent.
  • AMPK activator and PPARγ agonist. Adipogenesis inhibitor.
  • P2X7 receptor antagonist.
  • Wnt signaling & PI3K/Akt/GSK-3β pathway modulator.
Product References
  1. Vasorelaxant effect of emodin, an anthraquinone from a Chinese herb: H.C. Huang, et al.; Eur. J. Pharmacol. 205, 289 (1991)
  2. Emodin, a protein tyrosine kinase inhibitor from Polygonum cuspidatum: H. Jayasuriya, et al.; J. Nat. Prod.  55, 696 (1992)
  3. Emodin (3-methyl-1,6,8-trihydroxyanthraquinone) inhibits TNF-induced NF-kappaB activation, IkappaB degradation, and expression of cell surface adhesion proteins in human vascular endothelial cells: A. Kumar, et al.; Oncogene 17, 913 (1998)
  4. Emodin, an anthraquinone derivative isolated from the rhizomes of Rheum palmatum, selectively inhibits the activity of casein kinase II as a competitive inhibitor: H. Yim, et al.; Planta Med. 65, 9 (1999)
  5. Phytoestrogens from the roots of Polygonum cuspidatum (Polygonaceae): structure-requirement of hydroxyanthraquinones for estrogenic activity: H. Matsuda, et al.; Bioorg. Med. Chem. Lett. 11, 1839 (2001)
  6. Emodin induces apoptosis of human cervical cancer cells through poly(ADP-ribose) polymerase cleavage and activation of caspase-9: G. Srinivas, et al.; Eur. J. Pharmacol. 473, 117 (2003)
  7. Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth: T.L. Cha, et al.; Cancer Res. 65, 2287 (2005)
  8. Emodin inhibits vascular endothelial growth factor-A-induced angiogenesis by blocking receptor-2 (KDR/Flk-1) phosphorylation: H.J. Kwak, et al.; Int. J. Cancer 118, 2711 (2006)
  9. Emodin has a cytotoxic activity against human multiple myeloma as a Janus-activated kinase 2 inhibitor: A. Muto, et al.; Mol. Cancer Ther. 6, 987 (2007)
  10. Screening of Kit inhibitors: suppression of Kit signaling and melanogenesis by emodin: S.J. Lee, et al.; Phytother. Res. 24, 308 (2010)
  11. Neuroprotective effects of emodin in rat cortical neurons against beta-amyloid-induced neurotoxicity: T. Liu, et al.; Brain Res. 1347, 149 (2010)
  12. Inhibition of ATP-induced macrophage death by emodin via antagonizing P2X7 receptor: L. Liu, et al.; Eur. J. Pharmacol. 640, 15 (2010)
  13. Emodin, a natural product, selectively inhibits 11beta-hydroxysteroid dehydrogenase type 1 and ameliorates metabolic disorder in diet-induced obese mice: Y. Feng, et al.; Br. J. Pharmacol. 161, 113 (2010)
  14. Promotion of adiponectin multimerization by emodin: a novel AMPK activator with PPARγ-agonist activity: Z. Chen, et al.; J. Cell Biochem. 113, 3547 (2012)
  15. Antitumor activity of emodin against pancreatic cancer depends on its dual role: promotion of apoptosis and suppression of angiogenesis: S.Z. Lin, et al.; PLoS One 7, e42146 (2012)
  16. The distinct mechanisms of the antitumor activity of emodin in different types of cancer: W.T. Wei, et al.; Oncol. Rep. 30, 2555 (2013) (Review)
  17. Emodin suppresses Wnt signaling in human colorectal cancer cells SW480 and SW620: T. Pooja & D. Karunagaran; Eur. J. Pharmacol. 742, 55 (2014)
  18. Emodin induces neurite outgrowth through PI3K/Akt/GSK-3β-mediated signaling pathways in Neuro2a cells: S.J. Park, et al.; Neurosci. Lett. 588, 101 (2015)
  19. Anti-Inflammatory effect of emodin via attenuation of NLRP3 inflammasome activation: J.W. Han, et al.; Int. J. Mol. Sci. 16, 8102 (2015)
  20. Emodin reverses leukemia multidrug resistance by competitive inhibition and downregulation of P-glycoprotein: H. Min, et al.; PLoS One 12, e0187971 (2017)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.